Check out the Detailed Program! Learn More

Helicobacter pylori and its possible role in oesophageal disease

Helicobacter pylori is a bacterium that usually colonises the stomach and can cause chronic gastritis, peptic ulcer disease and, in some people, gastric cancer. Its relationship with the oesophagus is less direct. Researchers have examined whether infection alters reflux, Barrett’s oesophagus or oesophageal adenocarcinoma risk, yet findings remain complex and sometimes contradictory.

This question has practical relevance in Australia, where gastroenterologists, general practitioners and pathology services manage H. pylori alongside rising rates of gastro-oesophageal reflux disease. Understanding the evidence helps clinicians avoid assuming that every reflux symptom is caused by infection, or that eradication therapy will automatically protect the oesophagus.

Clinical issue What current evidence suggests Practical implication
Gastro-oesophageal reflux H. pylori may reduce acid production in some infected stomachs, but effects vary Do not use infection status alone to explain reflux
Barrett’s oesophagus Several studies report a lower prevalence among infected people, though confounding is substantial The association does not prove protection
Oesophageal adenocarcinoma An inverse association has been observed in some populations Eradication should follow established indications, not cancer-prevention assumptions
Oesophageal symptoms H. pylori is not usually a direct cause of dysphagia or oesophagitis Alarm symptoms require proper oesophageal assessment

How the stomach infection may affect the oesophagus

H. pylori can produce inflammation in the stomach lining and change the pattern of acid secretion. In some people, long-standing infection causes atrophic gastritis, which may reduce acid output. Lower acid exposure could theoretically lessen reflux-related injury to the oesophagus.

That biological explanation does not apply equally to every patient. Predominantly antral gastritis may increase acid secretion, while more extensive gastric atrophy may reduce it. Body weight, hiatal hernia, alcohol intake, smoking, medicines and meal patterns can have stronger effects on reflux symptoms than H. pylori status.

Links with reflux and Barrett’s oesophagus

Population studies have often found that H. pylori infection is less common in people with Barrett’s oesophagus than in control groups. Barrett’s develops when repeated reflux exposure causes changes in the lower oesophageal lining, and some researchers believe reduced gastric acidity could partly explain the observed inverse relationship.

The evidence is difficult to interpret because infection rates have fallen across wealthier countries while obesity, reflux disease and oesophageal adenocarcinoma have increased. These trends may reflect shared factors such as birth cohort, antibiotic exposure, socioeconomic conditions, diet and healthcare access rather than a direct protective effect from H. pylori.

What eradication treatment can and cannot do

Australian clinicians generally test and treat H. pylori when there is a recognised indication, such as current or previous peptic ulcer disease, selected dyspepsia presentations, gastric mucosa-associated lymphoid tissue lymphoma or a relevant family history of gastric cancer. Treatment usually combines acid suppression with two or more antibiotics, selected according to resistance patterns and previous antibiotic exposure.

Eradication is not a proven treatment for Barrett’s oesophagus, reflux oesophagitis or oesophageal cancer. Some patients experience more reflux symptoms after eradication, but this does not establish that treatment causes serious oesophageal disease. Confirming eradication with an appropriate breath or stool test is important, especially after complicated ulcer disease or treatment failure.

In Australia, antibiotics are prescription medicines regulated by the Therapeutic Goods Administration and supplied under state and territory medicines legislation. The Pharmaceutical Benefits Scheme may subsidise eligible treatment, while antimicrobial stewardship remains important because resistance to commonly used drugs can reduce success rates.

Australian considerations in diagnosis and care

A patient in Sydney or Melbourne may have relatively quick access to urea breath testing, specialist review and upper endoscopy, whereas someone in regional Western Australia, the Northern Territory or remote Queensland may face travel, waiting times and limited specialist availability. Telehealth can support follow-up, but it cannot replace endoscopy when there is progressive dysphagia, gastrointestinal bleeding, persistent vomiting or unexplained weight loss.

Australia’s multicultural population also matters. H. pylori prevalence is higher in some migrant communities and in settings associated with household crowding or reduced sanitation during childhood. Aboriginal and Torres Strait Islander communities experience significant health inequities, making culturally safe care, accessible testing and continuity of treatment particularly important.

Everyday habits can complicate symptom assessment. Large evening meals, frequent takeaway food, alcohol, smoking, sedentary routines and obesity may worsen reflux independently of infection. These factors should be assessed alongside medication use, including aspirin, anti-inflammatory drugs and over-the-counter acid suppressants.

Applying the evidence to patients

A positive H. pylori test should be interpreted as evidence of gastric infection, not as a diagnosis of oesophageal disease. A patient with heartburn may need lifestyle assessment and reflux management, while a patient with anaemia, bleeding, swallowing difficulty or suspected Barrett’s requires investigation based on clinical risk rather than H. pylori results.

The most reliable approach is to confirm the infection with a validated test, prescribe an evidence-based eradication regimen, check whether treatment succeeded and investigate persistent or alarming symptoms separately. For Australian practice, the practical takeaway is simple: treat H. pylori for established gastric indications, but assess oesophageal symptoms on their own clinical merits.

About ISDE

The ISDE is an international, multispecialty society devoted to the study of the esophagus in disease and in health that was founded in 1979. The aims of the ISDE are to promote the exchange of scientific and medical knowledge among specialists in the field, to maintain interchange with organizations and industries, and to encourage basic and clinical research in fields related to the esophagus. In order to promote the professional and educational development of individuals interested in the esophagus, the ISDE sponsors its own journal, international congresses, and other educational programs. The ISDE Secretariat was in Tokyo, Japan, from 1979 to 2004, and then resided in Los Angeles, California, from 2004 through 2010. Since 2010 the Secretariat has been in Vancouver, British Columbia, under the auspices of International Conferences Service, Ltd. The ISDE welcomes participation by existing members and encourages individuals who are professionally interested in the esophagus to become members. Benefits include reduced registration fees at our congresses and other educational offerings, restricted access to website content and member search capability, access to webcasts, reduced subscription rates for our journal, and the opportunity to help lead this organization into a position of leadership in the worldwide medical community.